Tuesday, 25 Feb 2020

You are here

Predictors of Serious Infections with Rituximab

The risk of serious infectious events (SIE) with rituximab (RTX) is similar to that seen in other biologics (e.g., RA: 2% or 4.3/100PY), but with prolonged use the risk may change. Recent research says that low IgG levels, RTX induced neutropenia, prior SIE and comorbidities can significantly augment this risk.

A retrospective longitudinal single center study of 700 rheumatic and musculoskeletal diseases (RMDs) treated monitored serum immunoglobulins (at baseline and 4–6 months after each cycle), clinical outcomes and SIE over time.

The patient population included rheumatoid arthritis (72%), systemic lupus erythematosus (13%),  ANCA‐associated vasculitis (7%) and 8% with other RMDs.

The overall SIE rate was 9.8/100 PY - 281 SIEs in 176 patients. Predictors of SIEs included:

  • non‐RTX‐specific comorbidities: prior history of SIE, cancer, chronic lung disease, diabetes, heart failure
  • higher corticosteroid doses
  • RTX‐specific factors;
    • low IgG(<6g/L) at baseline and subsequently
    • RTX‐associated neutropaenia
    • higher IgM
    • longer time‐to‐RTX retreatment

B‐cell depletion numbers were not predictive.

SIEs rates were even higher in those with low baseline IgG (16.4/100 PY) or acquired it during/post‐RTX (21.3/100 PY) when compared to those with normal IgG (9.7/100 PY). 

Monitoring B cell numbers does not appear to be as effective as monitoring serum IgG levels and neutrophils counts in patients who will receive long term or repeated RTX therapy.

Careful patient selection - those with no prior SIE and without comorbidities - may further limit the risk of SIE in such patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.

QD Clinic - Hepatitis B and Biologics

QD Clinic - Lessons from the clinic Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?

Biosimilars for Rheum Disease: Failure to Launch

The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.

Best of 2019 - Is Methotrexate Necessary with Tofacitinib?

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Best of 2019 - Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.